Bifidobacterium longum ATCC BAA-999 for Functional GI Disorders

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for functional gastrointestinal disorders (FGIDs) like Irritable Bowel Syndrome (IBS) demonstrate marginal efficacy and lack understanding of disease pathogenesis, with existing probiotics showing varying effectiveness and inadequate data on their efficacy.

Innovation Solution

A composition comprising Bifidobacterium longum ATCC BAA-999, which is commercially available, safe, and effective in treating or preventing FGIDs, administered orally or rectally in food products or dietary supplements, potentially interacting with the gut microbiota to alleviate symptoms.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If current treatments for FGIDs are used, then FGID symptoms are treated, but efficacy is marginal and understanding of pathogenesis is poor

Engineering Contradiction:

Improvetreatment efficacyVSAvoidunderstanding of disease pathogenesis

Core Design Contradiction:

ReliabilityVSLoss of information

Solution Approach 1:

The patent introduces probiotic bacteria as intermediary agents that mediate between the gut microbiota and FGID symptoms. These probiotics act as therapeutic intermediaries that can modulate the complex interactions within the gut ecosystem, providing a mechanism for treatment efficacy while offering insights into pathogenesis through their mode of action.

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent replaces conventional pharmaceutical treatments with a biological system-based approach using probiotics. This substitution moves from chemical/pharmacological mechanisms to biological mechanisms, enabling both treatment efficacy and enhanced understanding of pathogenesis through microbial ecology and immune modulation.

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

2Reliability

If existing probiotics are used, then some improvement in IBS symptoms is observed, but not all probiotics have equal efficacy and data is inadequate

Engineering Contradiction:

Improveprobiotic efficacy in IBSVSAvoidadequacy of efficacy data

Core Design Contradiction:

ReliabilityVSLoss of information

Solution Approach 1:

The patent applies parameter changes by specifying particular probiotic strains (e.g., Lactobacillus rhamnosus GG, Bifidobacterium longum NCC3001) with defined characteristics and dosages. This level of specificity transforms the vague parameter of 'probiotic efficacy' into measurable, reproducible parameters, generating adequate data through controlled studies of specific strains under defined conditions.

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent segments the broad category of probiotics into specific, well-defined strains with distinct functional characteristics. By dividing the heterogeneous group of probiotics into specific segments (particular strains with known mechanisms), the patent enables systematic evaluation of efficacy and generates adequate data through targeted research on individual strains rather than treating all probiotics uniformly.

Inventive Principle:

Principle #1Segmentation

3Ease of manufacture

If alternative bacterial strains are used, then cost-effectiveness and safety are improved, but need to demonstrate efficacy comparable to existing treatments

Engineering Contradiction:

Improvecost-effectiveness and safetyVSAvoidefficacy comparability

Core Design Contradiction:

Ease of manufactureVSReliability

Solution Approach 1:

The patent employs well-characterized, readily available probiotic strains that can be produced cost-effectively and safely. These strains represent accessible, economical alternatives to expensive conventional treatments, maintaining reliability through their proven safety profiles and mechanisms of action while being cost-effective to manufacture and administer.

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The use of Bifidobacterium longum ATCC BAA-999 significantly improves symptoms of FGIDs by modulating the gut microbiota, reducing inflammation, and enhancing BDNF expression, offering a cost-effective and side-effect-free alternative to existing treatments.

Implementation Method 1

The use of Bifidobacterium longum ATCC BAA-999 significantly improves symptoms of FGIDs by modulating the gut microbiota

Methodology Applied

Scientific EffectMicrobiota modulation:

Implementation Method 2

The use of Bifidobacterium longum ATCC BAA-999 significantly improves symptoms of FGIDs by modulating the gut microbiota, reducing inflammation

Methodology Applied

Scientific EffectAnti-inflammatory action:

Implementation Method 3

The use of Bifidobacterium longum ATCC BAA-999 significantly improves symptoms of FGIDs by modulating the gut microbiota, reducing inflammation, and enhancing BDNF expression

Methodology Applied

Scientific EffectBDNF expression enhancement:

Data Source

PatentUS11957720B2<i>Bifidobacterium longum </i>and functional GI disorders

Publication Date: 2024.04.16 SOCIETE DES PRODUITS NESTLE SA

AI summary

The present invention generally relates to the field of probiotic bacteria. In particular, it relates to methods for treating or preventing functional GI disorders comprising administering Bifidobacterium longum, such as Bifidobacterium longum ATCC BAA-999.